Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript Summary
Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript Summary
Operating loss decreased significantly to $1.5 million in Q3 2024 from $3.2 million in Q3 2023.The following is a summary of the Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript:
以下是Nuwellis公司（NUWE）2024年第三季度業績會議呼叫記錄摘要：
Financial Performance:
財務表現:
Nuwellis reported a Q3 revenue of $2.4 million, showing an 8% sequential growth but a 2% decrease from the previous year.
Gross margin improved significantly to 70% in Q3 2024 from 57.3% in Q3 2023.
Operating loss decreased significantly to $1.5 million in Q3 2024 from $3.2 million in Q3 2023.
Net income attributable to common shareholders was $2.4 million or $1.74 per share in Q3 2024, compared to a net loss of $3.4 million or a loss of $63.27 per share in Q3 2023.
Nuwellis報告第三季度營業收入爲240萬美元，環比增長8%，但較去年同期減少2%。
毛利率從2023年第三季度的57.3%顯著提高到2024年第三季度的70%。
運營虧損從2023年第三季度的320萬美元大幅減少至2024年第三季度的150萬美元。
歸屬於普通股股東的淨利潤爲240萬美元，每股1.74美元，相比於2023年第三季度的淨虧損340萬美元，每股虧損63.27美元。
Business Progress:
業務進展：
Expansion in pediatric customer account by 28%, driven by the opening of three new pediatric centers, including one in a major hospital network in Florida.
Growth supported by clinical evidence resulting in reduced 60-day hospital readmission rates in a community hospital trial of Aquadex therapy.
小兒客戶帳戶擴展28％，受三家新小兒中心開業的推動，其中包括在佛羅里達一個主要醫院網絡中開設的一個。
增長得到臨床證據支持，導致社區醫院試驗中Aquadex療法的60天再入院率降低。
Opportunities:
機會：
Anticipated increase in reimbursement rates for Aquadex ultrafiltration therapy by 297% starting January 1, 2025, could significantly boost revenue.
Increased outpatient usage of ultrafiltration could be more profitable for hospitals under new reimbursement rates, potentially replacing inpatient treatment and reducing readmissions.
預計2025年1月1日起，Aquadex超濾療法的報銷率將增加297%，可能會顯著提升營業收入。
超濾療法門診使用量增加可能對醫院更有利，在新的報銷率下可能取代住院治療並減少再次入院。
Risks:
風險：
Fluctuations in patient volumes, particularly in the critical care and heart failure categories, which declined by 25% and 36% respectively, due to seasonal impacts and lower consumable utilization.
患者人數波動，尤其是重症監護和心力衰竭類別，分別下降了25%和36%，因季節影響和低耗材利用而導致。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
